<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1 </plain></SENT>
<SENT sid="1" pm="."><plain>AE0047 is a new <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi> with protective effects against <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> and the occurrence of <z:hpo ids='HP_0001297'>stroke</z:hpo> in several animal models </plain></SENT>
<SENT sid="2" pm="."><plain>2 </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study we investigated whether AE0047 would improve the reduced cerebral blood flow (CBF) and <z:hpo ids='HP_0000969'>oedema</z:hpo> formation in cats subjected to middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion and compared it for efficacy with other <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> with different moieties, such as nilvadipine and nicardipine </plain></SENT>
<SENT sid="4" pm="."><plain>3 </plain></SENT>
<SENT sid="5" pm="."><plain>Middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> reduced local CBF (ICBF), as measured by the hydrogen clearance method, while dry weight measurement showed that water content in the cortical tissues surrounding each ICBF measurement electrode had increased after 4 h <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>4 </plain></SENT>
<SENT sid="7" pm="."><plain>Both AE0047 (10 micrograms/kg) and nilvadipine (30 micrograms/kg), given intravenously 20 min after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion, produced an approximate 10% hypotensive response and significantly increased ICBF in severely and moderately ischaemic regions, grouped according to the initial reduced flow values </plain></SENT>
<SENT sid="8" pm="."><plain>However, nicardipine (5 micrograms/kg bolus followed by infusion of 3 micrograms/kg per min for 60 min) failed to mitigate the reduction in ICBF despite an increase in the ICBF of the contralateral cortex </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, AE0047 tended to prevent an increase in cortical water content in severely ischaemic regions, whereas water content in both nilvadipine- and nicardipine-treated groups tended to increase </plain></SENT>
<SENT sid="10" pm="."><plain>5 </plain></SENT>
<SENT sid="11" pm="."><plain>These results suggest that <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> act differently on <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> and <z:hpo ids='HP_0000969'>oedema</z:hpo> formation in a manner dependent on their side-chain structures and that AE0047 effectively attenuates ischaemic brain damage without aggravating <z:hpo ids='HP_0000969'>oedema</z:hpo> </plain></SENT>
</text></document>